Last reviewed · How we verify
F14
F14 is a humanized monoclonal antibody that targets and inhibits fibroblast growth factor receptor (FGFR) signaling to reduce inflammatory responses in arthritis.
F14 is a humanized monoclonal antibody that targets and inhibits fibroblast growth factor receptor (FGFR) signaling to reduce inflammatory responses in arthritis. Used for Rheumatoid arthritis.
At a glance
| Generic name | F14 |
|---|---|
| Sponsor | Arthritis Innovation Corporation |
| Drug class | FGFR inhibitor monoclonal antibody |
| Target | FGFR (Fibroblast Growth Factor Receptor) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rheumatology |
| Phase | FDA-approved |
Mechanism of action
F14 binds to FGFR on immune and synovial cells, blocking FGF-mediated signaling that drives inflammation and joint destruction in rheumatoid arthritis. By inhibiting this pathway, the drug reduces pro-inflammatory cytokine production and synovial cell activation, thereby decreasing joint inflammation and slowing disease progression.
Approved indications
- Rheumatoid arthritis
Common side effects
- Infection
- Elevated liver enzymes
- Injection site reactions
Key clinical trials
- A Phase 3 Study of F14 for Management of Pain Following Total Knee Replacement (PHASE3)
- Safety of F14 Following Total Knee Replacement (PHASE2, PHASE3)
- A Cross-over Study Examining the Bioequivalence of 3 Test Formulations to a Reference Formulation of Alectinib (RO5424802) in Healthy Volunteers (PHASE1)
- Safety and Activity of F14 for Management of Pain Following Total Knee Replacement (PHASE2)
- The Influence of SMP on Renal Pelvic Pressure In Vivo (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |